Moderna says personalized mRNA cancer vaccine is effective for advanced melanoma

vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed.

Phase 3 is generally the largest and most expensive stage of clinical research before regulators review a potential drug for approval. In a mid-stage clinical trial involving 157 patients, researchers compared the vaccine-Keytruda combination with Keytruda alone. The treatments continued for about a year in both groups unless the disease came back or side effects became too severe.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna, Merck cancer vaccine combo cuts melanoma recurrence by 44%A combination of Moderna Inc's melanoma vaccine and Merck & Co's immunotherapy Keytruda cut the risk of skin cancer's recurrence or death by 44% compared with Keytruda alone in a mid-stage trial. Kind of convenient and good for NO BID PATENT PROFITS, that one jab causes a huge health problem, which can be 'solved' by another set of jabs, eh?
Source: Reuters - 🏆 2. / 97 Read more »